Company / Operating Cash Flow
Arrowhead Pharmaceuticals Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$179.6M
FY2025
5-year range
-$462.9M / $179.6M
FY2021-FY2025
Trend
+138.8%
vs FY2024
Sector context
#42 of 216
Health Care
What the data says
Arrowhead Pharmaceuticals's operating cash flow of $180M is higher than 81% of companies in the Health Care sector (FY2025). Operating Cash Flow has fluctuated over the past 10 years, ranging from -$463M in FY2024 to $180M in FY2025.
Based on SEC 10-K filings.
$180M in FY2025. Top quartile in the Health Care sector.
Improved from $171M to $180M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
-72.7% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 138.8% year-over-year.
- Ranks #42 out of 216 companies in the Health Care sector.
- Lowest operating cash flow in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $179.6M | +138.8% |
| FY2024 | -$462.9M | -370.2% |
| FY2023 | $171.3M | +278.8% |
| FY2022 | -$95.8M | -155.9% |
| FY2021 | $171.3M | +278.8% |
| FY2020 | -$95.8M | -300.2% |
| FY2019 | -$23.9M | +62.8% |
| FY2018 | -$64.4M | +1.9% |
| FY2017 | -$65.7M | -2.0% |
| FY2016 | -$64.4M | -238.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026